employing the systemic application of recombinant interleukin-2 ( il-2 ) in humans , rosenberg and colleagues from the national cancer institute reported the regression of advanced metastatic tumors in approximately 10 % -30 % of patients treated .
C0021756
recombinant interleukin-2
C0086418
humans